Imbruvik
(Ibrutinib)
(140 mg)
(90)
(Tablets)
Imbruvica (ibrutinib) 140 mg 90 tabs JANSEN Switzerland
Article:
Indications:
- Imbruvica is indicated for the treatment of mantle-clitinous lymphoma in adult patients who have relapsed or have not responded to previous treatment.
- Imbruvica is indicated for the treatment of chronic lymphocytic leukemia in adult patients who have received at least one course of treatment, or as first-line therapy for patients with a 17p deletion or TP53 mutation in patients who are not eligible for chemoimmunotherapy.
- 4800ct
-
Commercial name:Imbruvik
-
Сhemical name:Ibrutinib
-
Dosage:140 mg
-
Quantity:90
-
Release form:Tablets
No reviews yet